tbuckley/cabot-search huggingface dataset:
On the Bike Path, Riding Home
Authors: Judith Strasser
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Design and implementation of microarray gene expression markup language (MAGE-ML)
Authors: Paul T Spellman, Michael Miller, Jason Stewart, Charles Troup, Ugis Sarkans, Steve Chervitz, Derek Bernhart, Gavin Sherlock, Catherine Ball, Marc Lepage, Marcin Swiatek, WL Marks, Jason Goncalves, Scott Markel, Daniel Iordan, Mohammadreza Shojatalab, Angel Pizarro, Joe White, Robert Hubley, Eric Deutsch, Martin Senger, Bruce J Aronow, Alan Robinson, Doug Bassett, Christian J Stoeckert, Alvis Brazma
Journal: Genome biology (2002)

Meaningful exchange of microarray data is currently difficult because it is rare that published data provide sufficient information depth or are even in the same format from one publication to another. Only when data can be easily exchanged will the entire biological community be able to derive the full benefit from such microarray studies. To this end we have developed three key ingredients towards standardizing the storage and exchange of microarray data. First, we have created a minimal information for the annotation of a microarray experiment (MIAME)-compliant conceptualization of microarray experiments modeled using the unified modeling language (UML) named MAGE-OM (microarray gene expression object model). Second, we have translated MAGE-OM into an XML-based data format, MAGE-ML, to facilitate the exchange of data. Third, some of us are now using MAGE (or its progenitors) in data production settings. Finally, we have developed a freely available software tool kit (MAGE-STK) that eases the integration of MAGE-ML into end users' systems. MAGE will help microarray data producers and users to exchange information by providing a common platform for data exchange, and MAGE-STK will make the adoption of MAGE easier.
Abstract 9867: Insulating an Open Irrigated Ablation Electrode Improves Electrode Temperature Feedback for Radiofrequency Lesion Formation and Steam Pop
Authors: Atsushi Ikeda, Hiroshi Nakagawa, Fred H Wittkampf, Saurav Paul, Eric Hepler, Prathyusha Marri, Jan V Pitha, Tushar Sharma, Ralph Lazzara, Warren M Jackman
Journal: Circulation (2011)

Introduction: Open irrigation (Irg) cools electrode and electrode-tissue interface (ETI), and prevents thrombus while producing large RF lesions. However, electrode temperature (ET) does not predict excessive tissue heating and steam pop. The purpose of this study was to compare the relationship of ET to lesion size and steam pop between a novel thermally insulated Irg electrode (Gen2, St Jude Medical) and a conventional, non-insulated 4 mm Irg electrode (St Jude Medical) using a canine thigh muscle preparation. Methods: In 4 dogs, the skin over the thigh muscle was incised and raised to form a cradle, which was superfused with heparinized blood at 37°C. Gen2 has a 7F, 2.5 mm tip electrode with 6 proximal and 1 distal thermally insulated Irg channels to provide only external electrode cooling ( Fig A ). Gen2 and a conventional 7F, 4mm Irg catheter were held perpendicular or parallel to thigh muscle. Catheter-tissue contact force was applied at 5, 20 or 40 g. RF was applied for 60 sec at 20 W for Gen2 (Irg 17 ml/min) and 40 W for the 4mm electrode (Irg 17 ml/min). ET, ETI, and tissue temperatures (3 and 7mm depths) were measured. Dogs were sacrificed at 2 hours after ablation and lesion size was measured. Results: Table and Fig . Conclusions: Gen2 had a wider range of peak ET than 4 mm. Gen2 had better correlation between peak ET and lesion depth (R=0.71 vs. R=0.26), and between peak ET and steam pop (ET&gt;54°C vs. ET &gt;34°C).
Abstract 16846: Caregiver Symptoms and Burden 3 Weeks and 3 Months After Their Spouse’s Cardiac Surgery
Authors: Paula Schulz, Lani Zimmerman, Sue Barnason
Journal: Circulation (2014)

Introduction: Caregivers (CGs) play a major role in cardiac surgery patients’ recovery however, little research has examined the trajectory of burden and symptoms experienced by the CG. Hypothesis: The primary purpose of this longitudinal descriptive pilot study was to describe symptoms (fatigue/inertia, tension/anxiety, depression/dejection, and sleep difficulty) and their relationship to caregiving demand and difficulty in 28 adults caring for their spouses after cardiac surgery. Methods: Data were obtained telephonically 3 weeks and 3 months after surgery using the POMS-SF, Pittsburgh Sleep Quality Index and the Oberst Caregiving Burden Scale. Results: CGs (M = 68.5 ± 6.6 years) were primarily female (92%). In general, mean symptom scores were lower at 3 weeks and increased in severity at 3 months for fatigue/inertia (M = 3.0 ± 2.9 to 3.9 ± 3.6), depression/dejection (M = 1.3 ± 2.3 to 2.2 ± 3.8) and sleep difficulty (M = 3.3 ± 2.1 to 4.1 ± 2.5). Difficulty with caregiving tasks mean scores showed littl...
Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver
Authors: Yuma Yamada, Kohei Nakamura, Jiro Abe, Mamoru Hyodo, Sanae Haga, Michitaka Ozaki, Hideyoshi Harashima
Journal: Journal of Controlled Release (2015)
Long-term Outcomes for Extremely Low-Birth-Weight Infants—Reply
Authors: Maureen Hack, H. Gerry Taylor, Dennis Drotar, Mark Schluchter, Deanne Wilson-Costello, Nancy Klein
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Alcohol Warning Required for OTC Analgesic/Antipyretic Products
Authors: Stuart L. Nightingale
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The GMC: where now?
Authors: R. Smith
Journal: BMJ (2000)

To work effectively the General Medical Council needs the trust of the public, doctors, and government. At the moment it is trusted by none of them. Staying the same is no longer an option. So should the GMC opt for slow or rapid reform and in which direction? Or should the government appoint a royal commission to consider sweeping away the GMC?

High profile scandals have shaken public confidence in the regulation of doctors.1 Most important were the deaths of babies undergoing heart surgery in Bristol and the case of Harold Shipman, the general practitioner who was convicted of murdering 15 of his patients but who probably killed many more.2 3 The public has also been much concerned by reports in the media that the council has restored doctors to the medical register whom many people think should have been struck off forever.

The government has been doubtful about self regulation for a long time. It was some seven years ago that it set up a working party on poorly performing doctors, trespassing on an area that belonged to the GMC.4 Since then …
AASLD Abstracts 676-894
Authors: S Stevens, J Allen, A Murray, DE Jones, JL Newton
Journal: Hepatology (2008)

Fatigue is a significant problem that affects over 50% of patients with the autoimmune liver disease Primary Biliary Cirrhosis (PBC).To understand the biological basis of fatigue in PBC and to develop effective interventions, it is important that fatigue can be quantified accurately and reliably in PBC.Patient reports emphasise a perception that they experience "good days and bad days" suggesting the possibility of interday variability.The issue of variability in perception of fatigue during the course of the day has never been addressed.In this study we set out to address intra-and inter-day variability in fatigue perception in PBC to further inform the design of studies involving fatigue quantification in PBC and to help us to advise patients with regard to coping strategies.Sixteen female PBC patients and a fatigued control group of 25 CFS/ME (defined using Fukuda criteria) completed fatigue diaries.Subjects rated their fatigue on a scale of 0 (no fatigue) to 10 (severe fatigue) 4 times a day, each day for 5 weeks.In both PBC and CFS/ME there was no significant difference in perceived fatigue from week to week, or day to day.There were also no differences between week days and weekends or in the variability within days when considered between days.In PBC there was however a progressive and significant increase in perceived fatigue through each day, with mean ± SD fatigue scores of 3.2 ± 2 at breakfast increasing to 5.5 ± 2 at bedtime (p<0.001).This was in contrast to the CFS/ME population where fatigue was high in the morning (6.4 ± 2) lower at lunchtime (p<0.05), then increasing to 7 ± 2 at bedtime.Fatigue appears to be lowest in the morning in PBC increasing through the day which differs from the pattern seen in CFS/ME.This suggests that the biological mechanisms in the two fatigue associated diseases may be different.Furthermore, when assessing fatigue, it is important that this variability is considered and therefore assessment tools must be completed at a standardized time of day in PBC.Advising patients to plan their days, with a focus on performing activities in the morning if possible may help them to manage their symptoms.
Ovarian Cancer Investigators Aim at Cell Signaling PathwaysSeveral Groups Attempting Regulation of Internet Rx"Epidemic!" Exhibits Infectious Disease WorldConfidential Spanish Registry of HIV-Infected IndividualsOvarian Cancer Investigators Aim at Cell Signaling PathwaysSeveral Groups Attempting Regulation of Internet Rx"Epidemic!" Exhibits Infectious Disease WorldConfidential Spanish Registry of HIV-Infected Individuals
Authors: M J Friedrich
Journal: JAMA (1999)

HOUSTON—Identification of the cellular and genetic abnormalities involved in all types of cancer is providing new therapeutic avenues for researchers to pursue. Efforts to translate this knowledge into innovative therapies for ovarian cancer took the spotlight at the first International Conference on Ovarian Cancer, held at the University of Texas last month. Ovarian cancer, which has the highest mortality rate of all gynecologic cancers and is the fourth leading cause of cancer deaths among women in the United States, can usually be treated and cured if caught early. But all too often, it causes only vague symptoms that go unnoticed until the tumor is advanced and the prognosis is poor. To discuss the latest advances in treatment of the disease, several hundred gynecologic oncologists, medical oncologists, radiologists, other physicians, and oncology nurses from around the world attended the conference, which was cosponsored by M. D. Anderson Cancer Center here and Memorial SloanKettering Cancer Center in New York City. Gordon Mills, MD, PhD, chair of M.D. Anderson’s molecular oncology department, told the group, “The most important challenge we face over the next decade is to take the incredible understanding of cancer that we now have and start translating this intopatientmanagement.”
Findings in peripheral biopsy muscle in severe pneumonia due to H1N1 influenza
Authors: Maria Eugenia Dominguez Flores, Monica Velazquez, Rafael J. Hernandez-Zenteno, Francisca Fernandez Valverde, Steven Vargas Cañas, Alejandra Ramirez-Venegas, Jose Luis Tellez Becerra, Luis E. Payro, Omar Baños, Maria Eugenia Vazquez, Patricia Ledezma
Journal: European Respiratory Journal (2011)

Rationale: Myalgia and weakness are complications in H1N1 Influenza severe pneumonia (H1N1 ISP). Myopathy and polyneuropathy has been described only in Influenza B. Muscle damage in H1N1 ISP, has not been studied yet.

Objetive: To evaluate physiological, morphological and metabolic characteristics in muscle biopsies from patients with severe muscular weakness after a H1N1 ISP

Case report: After signed consent form 14 subjects with H1N1 ISP and muscular weakness were enrolled. Bilateral muscular strength (biceps and Quadriceps measured by electronic manometer) and electromyography and muscle biopsy (3-5 days after extubation) were performed.

Results: 

View this table:

General and Clinical characteristics





Conclusions: All patients with H1N1 ISP presented metabolic and physiological muscular alterations compatible with myopathy or myopathy/neuropathy. This findings explain the severe muscle symptoms and the low recovering even after discharge. An early physical rehabilitation program must be recommended.
Abstract 1660: Retroviral replicating vector transduced alloresponsive T lymphocytes retain mobility and cytotoxic functionalities
Authors: Kate L. Erickson, Colin C. Malone, Michelle J. Hickey, Geoffrey C. Owens, Yuki Kato, Robert M. Prins, Noriyuki Kasahara, Carol A. Kruse
Journal: Cancer Research (2014)

Abstract The radial monolayer cell migration assay was originally developed to measure the infiltrative properties of adherent tumor cells on individual extracellular matrix (ECM) proteins, or on ECM extracted from tumor cell monolayers. For this assay a single cell suspension of tumor cells is seeded using a cell sedimentation manifold (CSM), precisely into the center of Teflon-masked, ECM-coated slide wells. The adherent tumor cells establish a focal, circular monolayer from which horizontal motility can be microscopically-viewed and photographed over time. We adapted use of the CSM to evaluate the in vitro mobility of non-adherent effector T cells on confluent tumor cell monolayers or on ECM extracts from them. Cytotoxic T lymphocytes (CTL) sensitized to the human leukocyte antigens (HLA) on 13-06-MG glioma cells or on brain-tropic breast MDA-MB-231 carcinoma cells were generated by one-way mixed lymphocyte tumor cell reactions. These alloresponsive CTL were then transduced with retroviral replicating vectors (RRV) coding for green fluorescent protein (GFP). Using the CSM, the RRV-GFP transduced CTL were seeded into the center of wells with a confluent monolayer of glioma cells that were partially HLA matched to 13-06-MG. By light and fluorescence microscopy, we visualized not only the a) mobility of individual GFP+ T cells, but b) the cytotoxicity engendered to the underlying adherent glioma cell monolayer by the overlaid nonadherent CTL, in addition to c) transfer of RRV from the CTL to tumor cells. The in vitro cytotoxic functionality of the RRV-transduced CTL was confirmed by real-time xCELLigence impedance cytotoxicity assays. In other experiments, the RRV-GFP transduced CTL were also stained with a vital fluorescent red dye, CMPTX, to distinguish transduced from nontransduced CTL. The CTL were placed into the center of wells coated with ECM harvested from MDA-MB-231BR cells and radial movement of the transduced and nontransduced CTL was also observed over 72 hr time. We conclude that effector T cells transduced with RRV maintain mobility and cytotoxic functionality, and further, are capable of transmitting RRV to tumor cells. Thus, transduced alloresponsive CTL can facilitate immunogene therapy by their capability of gene delivery to infiltrating tumor cells in the brain. Citation Format: Kate L. Erickson, Colin C. Malone, Michelle J. Hickey, Geoffrey C. Owens, Yuki Kato, Robert M. Prins, Noriyuki Kasahara, Carol A. Kruse. Retroviral replicating vector transduced alloresponsive T lymphocytes retain mobility and cytotoxic functionalities. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1660. doi:10.1158/1538-7445.AM2014-1660
Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand
Authors: Steven A R Webb, Ville Yrjo Olavi Pettila, Ian M Seppelt, Rinaldo Bellomo, Michael John Bailey, David James Cooper, Michelle Cretikos, Andrew Ross Davies, Simon Finfer, Peter W J Harrigan, Graeme K Hart, Belinda Duval Howe, Jonathan R Iredell, Colin McArthur, Imogen Mitchell, Siouxzy Morrison, Alistair Dualta Nichol, David L Paterson, Sandra L Peake, Brent Richards, Dianne P Stephens, Andrew Turner, Michael Yung
Journal: New England Journal of Medicine (2009)

Planning for the treatment of infection with the 2009 pandemic influenza A (H1N1) virus through health care systems in developed countries during winter in the Northern Hemisphere is hampered by a lack of information from similar health care systems.We conducted an inception-cohort study in all Australian and New Zealand intensive care units (ICUs) during the winter of 2009 in the Southern Hemisphere. We calculated, per million inhabitants, the numbers of ICU admissions, bed-days, and days of mechanical ventilation due to infection with the 2009 H1N1 virus. We collected data on demographic and clinical characteristics of the patients and on treatments and outcomes.From June 1 through August 31, 2009, a total of 722 patients with confirmed infection with the 2009 H1N1 virus (28.7 cases per million inhabitants; 95% confidence interval [CI], 26.5 to 30.8) were admitted to an ICU in Australia or New Zealand. Of the 722 patients, 669 (92.7%) were under 65 years of age and 66 (9.1%) were pregnant women; of the 601 adults for whom data were available, 172 (28.6%) had a body-mass index (the weight in kilograms divided by the square of the height in meters) greater than 35. Patients infected with the 2009 H1N1 virus were in the ICU for a total of 8815 bed-days (350 per million inhabitants). The median duration of treatment in the ICU was 7.0 days (interquartile range, 2.7 to 13.4); 456 of 706 patients (64.6%) with available data underwent mechanical ventilation for a median of 8 days (interquartile range, 4 to 16). The maximum daily occupancy of the ICU was 7.4 beds (95% CI, 6.3 to 8.5) per million inhabitants. As of September 7, 2009, a total of 103 of the 722 patients (14.3%; 95% CI, 11.7 to 16.9) had died, and 114 (15.8%) remained in the hospital.The 2009 H1N1 virus had a substantial effect on ICUs during the winter in Australia and New Zealand. Our data can assist planning for the treatment of patients during the winter in the Northern Hemisphere.
The Human Adrenal Cortex: Its Function Throughout Life.
Authors: F. Verzár, G. E. W. Wolstenholme, Ruth Porter
Journal: Annals of Internal Medicine (1968)

are not currently found in the textbooks of clinical pathology.This 560-page volume consists of a series of over 50 articles, of which about half are concerned with the clinical aspects of biochemical, haematological, and bacteriological investigations, and the other articles, the technical details of carrying out some of these tests.There are 54 contributors.
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
Authors: Anna Goljan Geremek, Michal Bednarek, Elzbieta Puscinska, Adam Nowinski, Anna Kowalska, Monika Czystowska, Damian Korzybski, Dorota Górecka
Journal: European Respiratory Journal (2014)

OBJECTIVE :  Steroid treatment of sarcoidosis is associated with significant morbidity and has often been disappointing. Our objective was to evaluate the efficacy and safety of monotherapy with MTX in chronic sarcoidosis patients.  METHODS :  Between 2005 and 2013 MTX was used as a monotherapy in 53 patients (pts) (F:22, M: 31) with progressive disease. The dose ranged from 7,5mg to 20mg weekly. In 9 cases MTX was the first line therapy. 44 pts (83%) were refractory after steroid treatment.  RESULTS :    The duration of treatment ranged from 3 to 25 months.  The subjective intolerance was seen in 4pts. No severe adverse effects were observed in any case.  The symptomatic improvement was seen in 27pts (51%). The objective improvement was noted in:  27 pts (51%)- radiological improvement  23 pts (43%)- PFT and 6MWT improvement  6 pts (11%) had extra thoracic lesions reduction  In 12 pts (23%) progression of sarcoidosis was observed and steroid therapy was introduced. In 7 patients sarcoidosis relapsed after MTX being withdrawn.  The concomitant infection was the reason of discontinuation of therapy in 4 patients.  5 severe complication of sarcoidosis developed after the MTX therapy was finished:  2 cases of invasive aspergillosis (one fatal),  2 fatal cases of cardiovascular complications and 1 case of HCV infection.  CONCLUSION:  MTX as a single agent has proved to be safe and effective steroid alternative in selected sarcoidosis patients with chronic progressive sarcoidosis. Chronic progressive sarcoidosis is often associated with other comorbidities that may complicate the treatment. There is need to search for selection criteria to determine who may benefit from monotherapy with MTX.